Franklin Genomic Advancements ETF (HELX)

Assets	$21.34M
Expense Ratio	0.50%
PE Ratio	33.21
Shares Out	600,000
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a

Volume	10,405
Open	36.88
Previous Close	36.78
Day's Range	36.88 - 37.77
52-Week Low	23.74
52-Week High	37.77
Beta	1.07
Holdings	66
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: BATS
• Ticker Symbol: HELX
• ETF Provider: Franklin Templeton

Top 10 Holdings

45.43% of assets

Name	Symbol	Weight
Natera, Inc.	NTRA	6.96%
Guardant Health, Inc.	GH	6.82%
Insmed Incorporated	INSM	5.12%
Medpace Holdings, Inc.	MEDP	4.69%
Alnylam Pharmaceuticals, Inc.	ALNY	4.14%
Krystal Biotech, Inc.	KRYS	3.90%
Samsung Biologics Co.,Ltd.	207940	3.61%
United Therapeutics Corporation	UTHR	3.45%
Adaptive Biotechnologies Corporation	ADPT	3.40%
BridgeBio Pharma, Inc.	BBIO	3.34%

Performance

HELX had a total return of 26.50% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.21%.